Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy - The PEARL randomized cross-over study

European Journal of Pharmacology

Volumn 725, Issue 1, 2014, Pages 18-22

  Pelliccia, Francesco ^a   Rosano, Giuseppe ^b   Marazzi, Giuseppe ^b   Vitale, Cristiana ^b,c   Spoletini, Ilaria ^b   Franzoni, Ferdinando ^d   Speziale, Giuseppe ^e   Polacco, Marina ^a   Greco, Cesare ^a   Gaudio, Carlo ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c University Laboratory of Physiology   (United Kingdom)

^d UNIVERSITY OF PISA   (Italy)

^e Anthea Hospital GVM Care and Research   (Italy)

^f Eleonora Lorillard Spencer Cenci Foundation   (Italy)

Author keywords

Clopidogrel; Coronary artery disease; Percutaneous coronary intervention; Platelet reactivity

Indexed keywords

CLOPIDOGREL; CORONARY ARTERY DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY;

BLOOD PLATELETS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 84892930928     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.006     Document Type: Article

References (21)

1. D.J. Angiolillo, and F. Alfonso Clopidogrel-statin interaction: myth or reality? J. Am. Coll. Cardiol. 50 2007 296 298
2. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J. Am. Coll. Cardiol. 57 2011 1251 1263
3. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, R. Becker, D.L. Bhatt, M. Cattaneo, J.P. Collet, T. Cuisset, C. Gachet, G. Montalescot, L.K. Jennings, D. Kereiakes, D. Sibbing, D. Trenk, J.W. Van Werkum, F. Paganelli, M.J. Price, R. Waksman, and P.A. Gurbel Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J. Am. Coll. Cardiol. 56 2010 919 933
4. *2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting Heart 97 2011 1239 1244
5. S.S. Brar, J. ten Berg, R. Marcucci, M.J. Price, M. Valgimigli, H.S. Kim, G. Patti, N.J. Breet, G. DiSciascio, T. Cuisset, and G. Dangas Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data J. Am. Coll. Cardiol. 58 2011 1945 1954
6. M.J. Campbell, S.A. Julious, and D.G. Altman Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons B.M.J. 311 1995 1145 1148
7. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship gene polymorphisms clinical outcomes J. Am. Coll. Cardiol. 57 2011 2474 2483
8. T.A. Clarke, and A.L. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab. Dispos. 31 2003 53 59
9. C. Gachet ADP receptors of platelets and their inhibition Thromb. Haemost. 86 2001 222 232
10. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, A.S. Hopp, A.R. Tait, D.G. Carville, K.E. Guyer, and E.R. Bates Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
11. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, B. Cercek, C.E. Chambers, S.G. Ellis, R.A. Guyton, S.M. Hollenberg, U.N. Khot, R.A. Lange, L. Mauri, R. Mehran, I.D. Moussa, D. Mukherjee, B.K. Nallamothu, H.H. Ting, ACCF, AHA, and SCAI 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the, Society for Cardiovascular Angiography and Interventions J. Am. Coll. Cardiol. 58 2011 e44 e122
12. A. Malinin, A. Pokov, L. Swaim, M. Kotob, and V. Serebruany Validation of VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel Methods Find. Exp. Clin. Pharmacol. 28 2006 315 322
13. R.E. Malmström, J. Ostergren, L. Jørgensen, P. Hjemdahl CASTOR investigators Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment J. Intern. Med. 266 2009 457 466
14. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, C. Giglioli, P. Buonamici, D. Antoniucci, R. Abbate, and G.F. Gensini Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
15. Y. Park, Y.H. Jeong, U.S. Tantry, J.H. Ahn, T.J. Kwon, J.R. Park, S.J. Hwang, E.H. Gho, K.P. Bliden, C.H. Kwak, J.Y. Hwang, S. Kim, and P.A. Gurbel Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur. Heart J. 33 2012 2151 2162
16. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J. Am. Coll. Cardiol. 52 2008 1128 1133
17. M. Piorkowski, U. Weikert, P.L. Schwimmbeck, P. Martus, H.P. Schultheiss, and U. Rauch ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin Thromb. Haemost. 92 2004 614 620
18. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, J.P. Levisay, A. Ernst, N.S. Sawhney, R.A. Schatz, and P.S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J. 29 2008 992 1000
19. C. Saracini, A. Vestrini, S. Galora, A. Armillis, R. Abbate, and B. Giusti Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing Genet. Test. Mol. Biomark. 16 2012 500 503
20. S.R. Steinhubl, and W.S. Akers Clopidogrel-statin interaction: a mountain or a mole hill? Am. Heart J. 152 2006 200 203
21. P. Vinholt, T.S. Poulsen, L. Korsholm, S.R. Kristensen, J. Hallas, P. Damkier, and H. Mickley The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease J. Intern. Med. 266 2009 457 466